Horn Kinney sold $27K of IMNM
Horn Kinney (CHIEF BUSINESS OFFICER) sold 1,092 shares of Immunome Inc. (IMNM) at $25.00 on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the reported open-market sale by the company’s Chief Business Officer under a pre-arranged 10b5-1 plan; it does not include new company performance, guidance, or legal/clinical developments.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make it low-impact.
What to watch
The filing shows the insider ended with 0 shares, but it does not disclose reasons, future plans, or any concurrent company-specific catalyst.
Background
The article is a SEC Form 4 insider transaction disclosure for Immunome Inc. (IMNM).
Ticker impact
Horn Kinney, Immunome’s Chief Business Officer, sold 1,092 shares at $25.00 on 2026-07-07 under a 10b5-1 plan, leaving 0 shares.
Likely minimal immediate price impact; any effect would be sentiment-only and short-lived.
The filing is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan and the sale size is modest relative to typical market-moving thresholds.
Market effects
No clear sector read-through; this is company-specific insider dealing without operational or regulatory updates.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact if it treats it as discretionary selling.
Key entities
- issuerImmunome Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderHorn Kinney
Chief Business Officer who sold 1,092 shares under a 10b5-1 plan.